Compass Digital (NASDAQ:CDAQ) announced in an 8-K this morning that has sold the majority of its sponsor economics to HCG Opportunity.
The SPAC is parting with 3,093,036 promote shares (58.2%) and 3,000,000 private warrants (64.4%) and HCG will pay up to $300,000 to entities that are owed fees from Compass Digital. The SPAC’s original team is also to see its remaining 1,645,398 warrant count be reduced based on the final cash consideration in this deal.
The new team is one with serial SPAC experience. Daniel Hennessy is to be appointed as chairman, with Thomas Hennessy serving as CEO, Nick Geeza as CFO, while Kirk Hovde, Matt Schindel and Joseph Beck are to join the Board.
Daniel Hennessy has steered six SPACs that bore his name since 2014, while Thomas ran Proptech I and Proptech II. He recently also took over two (NYSE:TWOA) in a similar transaction.
The Hennessy-named SPACs have completed four deals, but Hennessy V liquidated in December and Hennessy VI (NASDAQ:HCVI) is still searching for a target. Proptechs I and II, meanwhile, each completed deals and two announced a combination last week under Hennessy’s management.
For now, Compass Digital has an estimated $221.7 million in trust and has not yet had to seek an extension, but it likely will before the new team completes a deal as its combination deadline is October 19.
Terms Tracker for the Week Ending October 25, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Finally, a little more SPAC action this week with no less than four IPOs priced. That brings October’s tally to seven IPOs with one more...
At the SPAC of Dawn The rebound of the growth companies that made up the SPAC class of 2021 has been one of the bigger stories of second half of 2024, but not all of the de-SPACs are feeling the love equally. Instead, in many new sectors that hit the public markets together as a...
DT Cloud (NASDAQ:DYCQ) has entered into a definitive agreement to combine with Maius Pharmaceutical at an equity value of $250 million. Shanghai-based Maius is a drug developer and researcher focused on small-molecule chemical treatments for different forms of cancer. The combined company is expected to trade on the Nasdaq once the deal is completed in...
Charlton Aria Acquisition Corporation announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHARU”, Thursday, October 24, 2024. The new SPAC plans to focus on industries that complement the management team’s and board of director’s background and network. The sponsor team for...
At the SPAC of Dawn As the market goes through a cooling period this week, new readouts for jobless claims and new home sales are set to hit later today. Jobless claims are of course something of a proxy indicator for SPACs as to when the Fed might continue to its rate-cutting process, while home...